Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.

Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.

Dr Geng discusses his research from AAAAI Annual Meeting, which explored the relationship between atopic dermatitis and comorbid atopic conditions.

Among patients aged 2 to 17 years with moderate to severe atopic dermatitis, tapinarof cream 1% significantly improved sleep, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than a quarter of patients achieved a clear or ...

Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved ...

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

Credit: Getty Images. No new safety signals were observed in this patient population. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ruxolitinib ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this ...